INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $428,000 | -66.8% | 17,363 | -44.2% | 0.04% | -68.8% |
| Q3 2020 | $1,290,000 | -39.5% | 31,125 | -8.1% | 0.11% | -51.9% |
| Q1 2020 | $2,132,000 | +354.6% | 33,878 | +505.0% | 0.23% | +2230.0% |
| Q2 2018 | $469,000 | -81.7% | 5,600 | -86.6% | 0.01% | -77.8% |
| Q1 2018 | $2,565,000 | -31.2% | 41,700 | +35.4% | 0.04% | -19.6% |
| Q2 2017 | $3,728,000 | +18.0% | 30,800 | +60.4% | 0.06% | -46.2% |
| Q3 2016 | $3,160,000 | +413.0% | 19,200 | +300.0% | 0.10% | +246.7% |
| Q1 2016 | $616,000 | -60.3% | 4,800 | -12.7% | 0.03% | -79.9% |
| Q1 2015 | $1,551,000 | – | 5,500 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |